Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
53 hedge funds and large institutions have $10.2M invested in Orexigen Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 8 closing their positions.
4% less funds holding
Funds holding: 55 → 53 (-2)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
58% less capital invested
Capital invested by funds: $24.2M → $10.2M (-$13.9M)
81% less call options, than puts
Call options by funds: $72K | Put options by funds: $378K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OWIM
Old West Investment Management
Los Angeles,
California
|
+$484K |
| 2 |
GL
GLG LLC
New York
|
+$65.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$65K |
| 4 |
Goldman Sachs
New York
|
+$43.1K |
| 5 |
Squarepoint
New York
|
+$36.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
-$2.05M |
| 2 |
Morgan Stanley
New York
|
-$829K |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$555K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$458K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$262K |
OREX Hedge Fund Activity: Q4 2016 in Review
53 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q4 2016, worth a combined $10.2M — down 58% from $24.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of OREX and 7 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 11 added.
The largest buyer was Old West Investment Management, opening a new position worth an estimated $484K. The largest seller was Samlyn Capital, exiting entirely with an estimated $2.05M sold.
- 53 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q4 2016, down from 55 in Q3 2016.
- Funds reported $10.2M of Orexigen Therapeutics, Inc. stock for Q4 2016, down 58% quarter-over-quarter.
- 7 funds opened new Orexigen Therapeutics, Inc. positions in Q4 2016 and 8 closed out, a net change of -1 holder.
- The largest Orexigen Therapeutics, Inc. buyer in Q4 2016 was Old West Investment Management, an estimated $484K added.
- The largest Orexigen Therapeutics, Inc. seller in Q4 2016 was Samlyn Capital, an estimated $2.05M sold.
Based on aggregated 13F filings for Q4 2016.